Holen Sie sich die Stockscreener-App
0.6869
4.06%
0.0268
Schlusskurs vom Vortag:
$0.6601
Offen:
$0.66
24-Stunden-Volumen:
835.80K
Relative Volume:
0.90
Marktkapitalisierung:
$86.68M
Einnahmen:
$140.46M
Nettoeinkommen (Verlust:
$-146.34M
KGV:
-0.5409
EPS:
-1.27
Netto-Cashflow:
$-117.73M
1W Leistung:
+8.48%
1M Leistung:
+8.17%
6M Leistung:
-22.82%
1J Leistung:
-10.33%
1-Tages-Spanne:
$0.651
$0.72
1-Wochen-Bereich:
$0.6126
$0.72
52-Wochen-Spanne:
$0.5809
$1.95
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Firmenname
Karyopharm Therapeutics Inc
Sektor
Branche
Telefon
617-658-0600
Adresse
85 WELLS AVENUE, NEWTON, MA
Vergleichen Sie KPTI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
0.6869 | 86.68M | 140.46M | -146.34M | -117.73M | -1.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-01-19 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-04 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-11-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-08-06 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-07-23 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-07-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-05 | Bestätigt | Robert W. Baird | Outperform |
| 2019-03-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-02-28 | Bestätigt | BofA/Merrill | Underperform |
| 2019-02-27 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | Eingeleitet | B. Riley FBR | Buy |
| 2018-11-09 | Hochstufung | Wedbush | Neutral → Outperform |
| 2018-05-24 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-04-02 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-11-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2016-09-08 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-30 | Hochstufung | Jefferies | Hold → Buy |
| 2016-08-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-06-28 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Karyopharm Therapeutics Inc Aktie (KPTI) Neueste Nachrichten
Karyopharm Therapeutics’ (KPTI) “Buy” Rating Reiterated at HC Wainwright - Defense World
What is HC Wainwright’s Estimate for KPTI FY2024 Earnings? - Defense World
What is HC Wainwright's Forecast for KPTI FY2024 Earnings? - MarketBeat
HC Wainwright Reiterates Buy Rating for Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat
Karyopharm Therapeutics' SWOT analysis: oncology firm's stock faces pivotal year - Investing.com India
Karyopharm Therapeutics’ SWOT analysis: oncology firm’s stock faces pivotal year - Investing.com Nigeria
Jane Street Group LLC Sells 1,345,226 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - MarketBeat
Jane Street Group LLC Has $170,000 Stake in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
KPTIKaryopharm Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
Karyopharm announces preliminary 2024 revenue - MSN
Karyopharm Reports $145M Revenue for 2024, Advances Phase 3 Myelofibrosis Trial - StockTitan
Why Karyopharm Therapeutics (KPTI) Is Among the Best Penny Stocks to Invest In According to Media? - MSN
Geode Capital Management LLC Has $1.13 Million Stake in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
Barclays PLC Has $79,000 Stock Holdings in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
Barclays PLC Sells 777,507 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - MarketBeat
Karyopharm CEO sells common stock for $3,175 By Investing.com - Investing.com Canada
12 Best Penny Stocks to Invest in According to the Media - Insider Monkey
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Position Reduced by State Street Corp - Defense World
Karyopharm appoints new CFO effective January 3 By Investing.com - Investing.com Australia
Karyopharm appoints new CFO effective January 3 - Investing.com India
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Karyopharm Appoints Lori Macomber as Chief Financial Officer - citybiz
Karyopharm Welcomes New Chief Financial Officer - Contract Pharma
Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer, Effective January 3, 2025 - Marketscreener.com
Karyopharm appoints new CFO to bolster financial strategy - Investing.com
Karyopharm Therapeutics names Lori Macomber as CFO - MSN
Karyopharm Appoints Lori Macomber as New CFO - TipRanks
Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer - Citizentribune
Karyopharm Therapeutics (NASDAQ:KPTI) Shares Pass Below 50 Day Moving AverageWhat's Next? - MarketBeat
KPTI stock touches 52-week low at $0.59 amid market challenges - Investing.com Canada
Karyopharm Therapeutics (STU:25K) Revenue per Share : €1.07 (TTM As of Sep. 2024) - GuruFocus.com
Lacklustre Performance Is Driving Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) 27% Price Drop - Simply Wall St
Fmr LLC Buys 76,510 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
KPTI stock touches 52-week low at $0.65 amid market challenges By Investing.com - Investing.com South Africa
KPTI stock touches 52-week low at $0.65 amid market challenges - Investing.com Canada
Karyopharm Therapeutics Inc.'s SWOT analysis: oncology firm's stock faces pivotal trials - Investing.com
Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024 - The Eastern Progress Online
Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications - Kilgore News Herald
Karyopharm Appoints Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications - citybiz
Finanzdaten der Karyopharm Therapeutics Inc-Aktie (KPTI)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):